Expand BBIO Menu
BBIO MENU

BBIO Latest Press Releases

-- November 25, 2025 --

BridgeBio to Participate in December Investor Conferences Globe Newswire 7:30 AM

-- November 19, 2025 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- November 8, 2025 --

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations Globe Newswire 10:41 AM

-- November 4, 2025 --

BridgeBio to Participate in November Investor Conferences Globe Newswire 7:30 AM

-- November 3, 2025 --

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 Globe Newswire 7:30 AM

-- October 29, 2025 --

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates Globe Newswire 4:01 PM
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 Globe Newswire 7:00 AM

-- October 28, 2025 --

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th Globe Newswire 4:01 PM

-- October 27, 2025 --

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study Globe Newswire 7:00 AM

-- October 24, 2025 --

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week Globe Newswire 4:01 PM

-- October 3, 2025 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 28, 2025 --

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM Globe Newswire 11:15 AM

-- September 22, 2025 --

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 Globe Newswire 7:30 AM

-- September 10, 2025 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 6, 2025 --

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism Globe Newswire 2:30 PM

-- September 3, 2025 --

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET Globe Newswire 7:30 AM

-- September 2, 2025 --

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism Globe Newswire 7:30 AM

-- September 1, 2025 --

BridgeBio presents data from ATTRibute-CM open label extension through month 42 TipRanks 8:39 AM

-- August 30, 2025 --

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension Globe Newswire 7:15 AM

-- August 27, 2025 --

BridgeBio to Participate in September Investor Conferences Globe Newswire 7:30 AM

-- August 25, 2025 --

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 Globe Newswire 7:30 AM

-- August 6, 2025 --

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics Globe Newswire 7:33 AM

-- August 5, 2025 --

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes